When assessed in vivo, TGFβ-resistant EGFRvIII-CAR T-cells had a significantly greater reduction in tumor burden, prolonged the survival of xenografted mice, and significantly improved CAR T-cell infiltration into glioma sites compared to unmodified CAR T-cells. This evidence concerns the gene TGFB1 and neoplasm.